Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 224

1.

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, Siddiqui FA, Hargrave T, Kwo PY, Lambiase L, Galler GW, Araya V, Freilich B, Harvey J, Griffel LH, Brass CA; WIN-R Study Group.

Hepatology. 2007 Oct;46(4):982-90.

PMID:
17894323
[PubMed - indexed for MEDLINE]
2.

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.

Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA; WIN-R Study Group.

Hepatology. 2007 Oct;46(4):971-81.

PMID:
17894303
[PubMed - indexed for MEDLINE]
3.
4.

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.

Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serrão R, Sola R, Bertasso A, Passe And S, Stancic S.

HIV Clin Trials. 2012 May-Jun;13(3):142-52. doi: 10.1310/hct1303-142.

PMID:
22592094
[PubMed - indexed for MEDLINE]
5.

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.

J Hepatol. 2010 Apr;52(4):501-7. doi: 10.1016/j.jhep.2010.01.016. Epub 2010 Feb 4.

PMID:
20189674
[PubMed - indexed for MEDLINE]
6.

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

McHutchison J, Sulkowski M.

J Viral Hepat. 2008 Jul;15(7):475-81. doi: 10.1111/j.1365-2893.2008.00973.x. Epub 2008 Mar 24.

PMID:
18363672
[PubMed - indexed for MEDLINE]
7.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR.

Am J Gastroenterol. 2005 Nov;100(11):2453-62.

PMID:
16279900
[PubMed - indexed for MEDLINE]
8.

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.

Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G.

Gastroenterology. 2010 Jan;138(1):116-22. doi: 10.1053/j.gastro.2009.10.005. Epub 2009 Oct 20.

PMID:
19852964
[PubMed - indexed for MEDLINE]
9.

Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.

Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S.

J Clin Gastroenterol. 2010 Feb;44(2):140-5. doi: 10.1097/MCG.0b013e3181ba9992.

PMID:
19826275
[PubMed - indexed for MEDLINE]
10.

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG.

Hepatology. 2008 Aug;48(2):407-17. doi: 10.1002/hep.22403.

PMID:
18666223
[PubMed - indexed for MEDLINE]
11.

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman D, Chun E, Hammond J.

Hepatology. 2010 Oct;52(4):1208-15. doi: 10.1002/hep.23827.

PMID:
20721883
[PubMed - indexed for MEDLINE]
12.

Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.

Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K.

J Gastroenterol Hepatol. 2009 Mar;24(3):366-71. doi: 10.1111/j.1440-1746.2008.05650.x. Epub 2008 Nov 20.

PMID:
19032459
[PubMed - indexed for MEDLINE]
13.

Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.

Zopf S, Herold C, Hahn EG, Ganslmayer M.

Scand J Gastroenterol. 2009;44(4):486-90. doi: 10.1080/00365520802647400.

PMID:
19117241
[PubMed - indexed for MEDLINE]
14.

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.

Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators.

Hepatology. 2010 Oct;52(4):1201-7. doi: 10.1002/hep.23816.

PMID:
20683847
[PubMed - indexed for MEDLINE]
15.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators.

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

PMID:
23768747
[PubMed - indexed for MEDLINE]
16.

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H.

J Hepatol. 2011 Sep;55(3):554-63. doi: 10.1016/j.jhep.2010.12.024. Epub 2011 Jan 13.

PMID:
21237227
[PubMed - indexed for MEDLINE]
17.

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R.

Hepatology. 2002 Apr;35(4):930-6.

PMID:
11915041
[PubMed - indexed for MEDLINE]
18.

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.

Brady DE, Torres DM, An JW, Ward JA, Lawitz E, Harrison SA.

Clin Gastroenterol Hepatol. 2010 Jan;8(1):66-71.e1. doi: 10.1016/j.cgh.2009.08.036. Epub 2009 Sep 10.

PMID:
19747986
[PubMed - indexed for MEDLINE]
19.

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.

Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group.

Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130.

PMID:
19676125
[PubMed - indexed for MEDLINE]
20.

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS.

Hepatology. 2010 Sep;52(3):864-74. doi: 10.1002/hep.23787.

PMID:
20568303
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk